Principal Securities’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Principal Securities’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-212	Closed	-$17.7K	–	3920
2025 Q1	$17.7K	Hold	212	–	–	﹤0.01%	2267
2024 Q4	$17.7K	Hold	212	–	–	﹤0.01%	2265
2024 Q3	$15.5K	Sell	212 -42	-17%	-$3.16K	﹤0.01%	2248
2024 Q2	$17.4K	Sell	254 -1	-0.4%	-$69	﹤0.01%	2125
2024 Q1	$17.6K	Sell	255 -31	-11%	-$2.13K	﹤0.01%	2064
2023 Q4	$20.5K	Buy	+286	New	+$16.5K	﹤0.01%	1906

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Principal Securities's ITCI Position: Q2 2025 in Review

Principal Securities sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 212 shares — an estimated $17.7K sold.

Principal Securities first reported a position in ITCI in Q4 2023 and held it in 6 quarters. The position peaked at $20.5K in Q4 2023. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Principal Securities reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Principal Securities sold 212 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $17.7K.
Principal Securities first reported a position in Intra-Cellular Therapies Inc. in Q4 2023 and held it in 6 quarters.
Principal Securities's Intra-Cellular Therapies Inc. position peaked at $20.5K in Q4 2023.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Principal Securities's 13F filing for Q2 2025, filed 11 Aug 2025.